-
Self-monitoring strategy reduces postpartum hypertension and cardiac remodelling Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-28 Karina Huynh
In women with elevated levels of blood pressure during pregnancy, the use of a physician-guided remote telemonitoring programme during the postpartum period improves BP control, according to findings from the POP-HT trial.
-
Aspirin exclusion in patients with an LVAD Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-27 Gregory B. Lim
Data from the ARIES-HM3 trial show that excluding aspirin from the antithrombotic regimen in patients with advanced heart failure and a left ventricular assist device reduces the number of bleeding events and does not increase the risk of thromboembolism.
-
Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-24 Mattia Galli, Giampaolo Niccoli, Gianluigi De Maria, Salvatore Brugaletta, Rocco A. Montone, Rocco Vergallo, Stefano Benenati, Giulia Magniani, Domenico D’Amario, Italo Porto, Francesco Burzotta, Antonio Abbate, Dominick J. Angiolillo, Filippo Crea
-
Long non-coding RNAs in cardiac hypertrophy and heart failure: functions, mechanisms and clinical prospects Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-20 John D. Mably, Da-Zhi Wang
-
Explaining how a cardiac reflex causes syncope Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-14 Gregory B. Lim
Activation of a specific set of vagal sensory neurons connecting the ventricular wall of the heart to the area postrema in the brainstem causes mice to faint. This finding defines a cardiac reflex that recapitulates characteristics of human syncope.
-
Revealing the structure of the cardiac myosin filament Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-14 Gregory B. Lim
Two new studies using cryo-electron microscopy describe the structure and conformation of myosin in the cardiac thick filaments and how it interacts with other thick-filament proteins, such as titin and cardiac myosin-binding protein C, in mammalian hearts.
-
Disrupting a cell-specific miRNA–CXCR4 interaction is atheroprotective in mice Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-13 Irene Fernández-Ruiz
An approach that increases the expression of the chemokine receptor CXCR4 in vascular cells by targeting a microRNA-based repressive pathway attenuates atherosclerosis in mice and promotes atheroprotective functions in human and mouse vascular cells in vitro.
-
Lipoprotein(a), platelet function and cardiovascular disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-08 Harpreet S. Bhatia, Richard C. Becker, Gregor Leibundgut, Mitul Patel, Paul Lacaze, Andrew Tonkin, Jagat Narula, Sotirios Tsimikas
-
Patisiran is beneficial for the treatment of TTR cardiac amyloidosis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-06 Irene Fernández-Ruiz
Treatment with the small interfering RNA patisiran preserves functional capacity and improves health status and quality of life in patients with transthyretin cardiac amyloidosis, according to data from the 12-month double-blind period of the ongoing APOLLO-B trial.
-
Drug-eluting resorbable scaffolds are superior to angioplasty for infrapopliteal artery disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-06 Karina Huynh
In the LIFE-BTK trial, treatment with an everolimus-eluting resorbable scaffold was superior to angioplasty in improving clinical outcomes in patients with chronic limb-threatening ischaemia due to infrapopliteal artery disease.
-
Long-term outcomes and device failure after TAVI Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-03 Marco Barbanti, John G. Webb
-
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-03 Stefano Toldo, Antonio Abbate
-
2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-02 Joselyn Rwebembera, James Marangou, Julius Chacha Mwita, Ana Olga Mocumbi, Cleonice Mota, Emmy Okello, Bruno Nascimento, Lene Thorup, Andrea Beaton, Joseph Kado, Alexander Kaethner, Raman Krishna Kumar, John Lawrenson, Eloi Marijon, Mariana Mirabel, Maria Carmo Pereira Nunes, Daniel Piñeiro, Fausto Pinto, Kate Ralston, Craig Sable, Amy Sanyahumbi, Anita Saxena, Karen Sliwa, Andrew Steer, Satupaitea
-
Restoration of flow in the aorta: a novel therapeutic target in aortic valve intervention Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-25 Pankaj Garg, Michael Markl, Janarthanan Sathananthan, Stephanie L. Sellers, Chris Meduri, João Cavalcante
-
Defining iron deficiency in patients with heart failure Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-24 John G. F. Cleland
-
Sirtuin 2 protects against cardiac ageing Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-18 Irene Fernández-Ruiz
NAD-dependent protein deacetylase sirtuin 2 is a key protective mediator against cardiac ageing, according to a study in non-human primates.
-
SARS-CoV-2 infects macrophages in coronary atherosclerotic plaques Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-18 Gregory B. Lim
SARS-CoV-2 infects macrophages, especially lipid-laden foam cells, in coronary atherosclerotic plaques in patients with COVID-19; this infection initiates a strong proatherogenic inflammatory response, which might contribute to the ischaemic cardiovascular complications in these patients.
-
Depolarization of fibroblasts in scar tissue drives cardiac excitation Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-17 Karina Huynh
In a study published in Science, Wang and colleagues show that excited cardiomyocytes couple to fibroblasts via gap-junctional and non-gap-junctional (ephaptic) coupling.
-
Oxidized phospholipids in cardiovascular disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-17 Sotirios Tsimikas, Joseph L. Witztum
-
Capturing and analysing the first vertebrate heartbeat Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-13 Karina Huynh
In a study published in Nature, Jia and colleagues use advanced optical electrophysiology tools coupled with 3D-printed moulds to capture the very first heartbeat of zebrafish.
-
Metabolic reprogramming unlocks the regenerative potential of the heart Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-13 Irene Fernández-Ruiz
The metabolic maturation of mammalian cardiomyocytes that occurs during the early postnatal period shapes the epigenetic landscape of cardiomyocytes and creates a barrier for cell division, but reversing this remodelling process can restore the reparative capacity of the heart in mice, according to a study published in Nature.
-
Socioeconomic inequalities in cardiovascular disease: a causal perspective Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-11 David Bann, Liam Wright, Alun Hughes, Nish Chaturvedi
-
Cardiovascular physiology and pathophysiology at high altitude Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-02 Jean-Paul Richalet, Eric Hermand, François J. Lhuissier
-
Cardiovascular benefits of fermented foods and beverages: still up for debate Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-02 Ramon Estruch, Rosa M. Lamuela-Raventós
-
Sex-specific and ethnicity-specific differences in MINOCA Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-29 Sarena La, John Beltrame, Rosanna Tavella
-
The menopausal transition period and cardiovascular risk Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-26 Jaya M. Mehta, JoAnn E. Manson
-
Effects of lifestyle factors on leukocytes in cardiovascular health and disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-26 Henrike Janssen, Laura L. Koekkoek, Filip K. Swirski
-
Prehabilitation: evolving role in contemporary cardiac surgery Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-25 Atilio Barbeito, Daniel E. Forman
The population of patients who undergo cardiac surgery is becoming older and more medically complex, and frailty is increasingly prevalent. Prehabilitation is a multicomponent programme intended to better prepare these vulnerable patients for the stresses of surgery. Nonetheless, the effectiveness, implementation and effects on long-term outcomes of prehabilitation have not been clearly established
-
CHIP in HF: prognostic role and cell-intrinsic effects Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-20 Karina Huynh
Two studies now report that TET2-driven clonal haematopoiesis of indeterminate potential (CHIP) is associated with poor prognosis in patients with heart failure (HF) and preserved ejection fraction and that DNMT3A CHIP driver mutations promote dysregulated gene expression profiles that are associated with inflammation in monocytes in the setting of HF.
-
Migraines and cardiovascular disease: mechanisms and methodological challenges Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-18 Tobias Kurth, Pamela M. Rist
The link between migraine and cardiovascular disease is complex and involves overlapping mechanisms, such as endovascular disturbances. Challenges in measuring migraine, in distinguishing between causation and prediction, and in the understanding of clinical implications highlight the need for further research to guide treatment and cardiovascular risk assessment for the millions of individuals living
-
Semaglutide is beneficial in patients with HFpEF and obesity Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-14 Irene Fernández-Ruiz
In patients with heart failure (HF) with preserved ejection fraction and obesity, treatment with the glucagon-like peptide 1 receptor agonist semaglutide (2.4 mg) leads to large reductions in HF-related symptoms and physical limitations, improves exercise function and decreases body weight compared with placebo, according to the STEP-HFpEF trial.
-
Immunomodulation and immunopharmacology in heart failure Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-14 George Markousis-Mavrogenis, Lukas Baumhove, Ali A. Al-Mubarak, Joseph Pierre Aboumsallem, Nils Bomer, Adriaan A. Voors, Peter van der Meer
-
Complete revascularization in MI: role in older patients and optimal timing Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-13 Karina Huynh
The FIRE trial showed that complete revascularization improves outcomes in older patients with myocardial infarction (MI) and multivessel disease compared with culprit-lesion-only revascularization, whereas the MULTISTARS AMI trial reported that immediate multivessel revascularization is non-inferior to staged revascularization in patients with ST-segment elevation MI.
-
Age-induced senescence impairs the neurovascular interface in the heart Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-13 Jennifer Harman
An interaction between blood vessels and nerve fibres in the heart contributes to the decline in nerve density in the ageing left ventricle, potentially increasing susceptibility to arrhythmias.
-
Catheter ablation improves outcomes in patients with AF and end-stage HF Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-11 Karina Huynh
In the CASTLE HTx trial, patients with symptomatic atrial fibrillation and end-stage heart failure who underwent catheter ablation and received medical therapy had improved outcomes compared with patients who received medical therapy only.
-
VA-ECMO does not increase survival in MI-related cardiogenic shock Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-06 Gregory B. Lim
New data from the ECLS-SHOCK trial and a meta-analysis indicate that the routine use of venoarterial extracorporeal membrane oxygenation does not increase survival in patients with myocardial infarction-related cardiogenic shock.
-
New insights into OCT-guided PCI Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-05 Irene Fernández-Ruiz
Two clinical trials presented at the ESC Congress 2023 provide conflicting evidence on the use of optical coherence tomography to guide percutaneous coronary intervention.
-
No benefit of colchicine to prevent AF or myocardial injury after non-cardiac surgery Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-04 Gregory B. Lim
According to data from the COP-AF trial, anti-inflammatory therapy with colchicine does not reduce the risk of perioperative atrial fibrillation or myocardial injury in patients undergoing major non-cardiac thoracic surgery.
-
Non-steroidal mineralocorticoid receptor antagonists in heart failure Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-29 Gerasimos Filippatos, Dimitrios Farmakis
-
Circadian medicine: a critical strategy for cardiac care Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-29 Michael J. Sole, Tami A. Martino
-
Interatrial shunt devices for heart failure Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-25 Finn Gustafsson
Unloading left atrial hypertension by catheter-based, transvenous creation of atrial shunts is being explored to treat heart failure. So far, trials including sham control have demonstrated safety and efficacy in lowering left-sided cardiac filling pressures. Ongoing trials will determine the effect on clinical outcomes.
-
Pitavastatin reduces cardiovascular events in patients with HIV infection Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-16 Karina Huynh
In the REPRIEVE trial, pitavastatin treatment in patients with human immunodeficiency virus (HIV) infection without pre-existing cardiovascular disease prevented cardiovascular events compared with placebo.
-
Heart disease causes sleep disturbances via neuroimmune mechanisms Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-14 Irene Fernández-Ruiz
A new study reveals that the disrupted sleep patterns that are frequently observed in patients with cardiac disease are driven by immune-mediated sympathetic denervation and dysfunction of the pineal gland, which leads to a decrease in the circulating levels of melatonin and subsequent sleep disruption.
-
Animal models to study cardiac regeneration Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-14 Michael Weinberger, Paul R. Riley
-
Valvular heart disease and cardiomyopathy: reappraisal of their interplay Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-10 Nina Ajmone Marsan, Francesca Graziani, Maria Chiara Meucci, Hoi W. Wu, Rosa Lillo, Jeroen J. Bax, Francesco Burzotta, Massimo Massetti, J. Wouter Jukema, Filippo Crea
-
The role of cardiac pericytes in health and disease: therapeutic targets for myocardial infarction Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-04 Elisa Avolio, Paola Campagnolo, Rajesh Katare, Paolo Madeddu
-
Novel macrophage targets for the treatment of atrial fibrillation Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-02 Karina Huynh
A study shows that macrophages undergo substantial expansion in the diseased atria of patients with atrial fibrillation (AF), and identifies two potential immunotherapy targets for the treatment of AF.
-
Cholesterol catabolism and bile acid synthesis in cardiomyocytes promote inflammation and heart failure Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-31 Gregory B. Lim
In failing cardiomyocytes, depletion of carnitine acetyltransferase promotes cholesterol catabolism via the bile acid synthesis pathway. The intracellular accumulation of bile acid intermediates induces the release of mitochondrial DNA into the cytosol, triggering type I interferon responses and AIM2 inflammasome activation, thereby contributing to chronic myocardial inflammation and heart failure
-
Promising novel siRNA for the treatment of hypertension Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-31 Irene Fernández-Ruiz
Patients with hypertension who receive a single subcutaneous dose of zilebesiran, a novel small-interfering RNA that inhibits hepatic angiotensinogen synthesis, have reductions in serum angiotensinogen levels and 24-h ambulatory blood pressure that last for up to 24 weeks, according to a phase I study.
-
Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-26 Daniel J. Piñeiro, Elisa Codato, Jeremiah Mwangi, Jean-Luc Eiselé, Jagat Narula
-
Unravelling ACS pathophysiology using intracoronary OCT and deep immunophenotyping Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-25 Jennifer Harman
According to two papers from the OPTICO-ACS study, patients with acute coronary syndrome and an intact fibrous cap (plaque erosion), tend to have lower levels of inflammation and better prognosis than patients with rupture of the fibrous cap. In addition, Toll-like receptor 2-mediated neutrophil activation has a key role in plaque erosion.
-
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-20 Diana A. Gorog, Jose Luis Ferreiro, Ingo Ahrens, Junya Ako, Tobias Geisler, Sigrun Halvorsen, Kurt Huber, Young-Hoon Jeong, Eliano P. Navarese, Andrea Rubboli, Dirk Sibbing, Jolanta M. Siller-Matula, Robert F. Storey, Jack W. C. Tan, Jurrien M. ten Berg, Marco Valgimigli, Christophe Vandenbriele, Gregory Y. H. Lip
-
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-18 Bernhard Föllmer, Michelle C. Williams, Damini Dey, Armin Arbab-Zadeh, Pál Maurovich-Horvat, Rick H. J. A. Volleberg, Daniel Rueckert, Julia A. Schnabel, David E. Newby, Marc R. Dweck, Giulio Guagliumi, Volkmar Falk, Aldo J. Vázquez Mézquita, Federico Biavati, Ivana Išgum, Marc Dewey
-
Heart transplantation: advances in expanding the donor pool and xenotransplantation Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-14 Stephanie Jou, Sean R. Mendez, Jason Feinman, Lindsey R. Mitrani, Valentin Fuster, Massimo Mangiola, Nader Moazami, Claudia Gidea
-
FGF23 and klotho at the intersection of kidney and cardiovascular disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-13 Daniel Edmonston, Alexander Grabner, Myles Wolf
-
Ruxolitinib is a CaMKII inhibitor that can be repurposed to prevent arrhythmias Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-03 Karina Huynh
The FDA-approved drug ruxolitinib has been identified as an inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII) that has the potential to be repurposed to treat arrhythmias induced by CaMKII hyperactivity.
-
RAPID return to sinus rhythm after SVT using intranasal etripamil Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-03 Karina Huynh
In the multicentre, randomized, placebo-controlled RAPID trial, use of symptom-prompted, self-administered, intranasally delivered etripamil was safe and superior to placebo for the conversion of paroxysmal superventricular tachycardia to sinus rhythm.
-
Testosterone-replacement therapy does not increase cardiac events in men with hypogonadism Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-30 Gregory B. Lim
Testosterone-replacement therapy in men with hypogonadism and a high risk of cardiovascular disease does not increase the risk of adverse cardiac events, according to data from the TRAVERSE trial.
-
Low alcohol intake might lower CVD risk by reducing stress-related brain activity Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-26 Irene Fernández-Ruiz
New research shows that the reduced risk of major adverse cardiovascular events associated with light or moderate alcohol consumption is partly mediated by attenuation of the activity of a stress-related neural network.
-
IL-6R antagonism ameliorates atherosclerosis linked to Tet2-related clonal haematopoiesis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-26 Karina Huynh
Liu and colleagues demonstrate the crucial role of IL-6 signalling in the development of atherosclerosis driven by Tet2-related clonal haematopoiesis.